(Reuters) -AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and ...

AbbVie Inc.’s stock rose 5% early Friday to lead S&P 500 gainers premarket, after the drug company beat fourth-quarter ...

AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq ...

The North Chicago-based drugmaker is relying on newer treatments to make up for falling sales of Humira, its aging ...

NORTH CHICAGO, Ill. (AP) — NORTH CHICAGO, Ill. (AP) — AbbVie Inc. (ABBV) on Friday reported a fourth-quarter loss of $22 million, after reporting a profit in the same period a year earlier.

AbbVie (ABBV) is up 7.8%, or $13.78 to $189.43.Invest with Confidence: Follow TipRanks' Top Wall Street Analysts to uncover their success rate ...

EST AbbVie (ABBV) seeing ‘significant advancements’ across entire pipelineInvest with Confidence: Follow TipRanks' Top Wall Street ...

Britain's health security agency said on Friday another case of the mpox variant clade lb has been detected in England, the ...

AbbVie shares surged nearly 8% Friday morning, after the company substantially raised its sales forecasts for two key drugs. While reporting fourth-quarter revenue and earnings per share above Wall ...

AbbVie saw fourth-quarter sales handily beat Wall Street's projections as gains from its newer anti-inflammatory drugs helped offset declines from Humira, once its best performing asset. The drugmaker ...

AbbVie (ABBV), a large drug maker, is jumping 8% after the company provided significantly higher-than-expected 2025 earnings per share guidance this morning. Additionally, the company’s Q4 revenue ...